Isofol has obtained a request to call for an extraordinary general meeting
GOTHENBURG, Sweden, January 30, 2023 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL), has obtained a request to call an […]
Listing Regulation
Isofol invites to an informational meeting on January 30 prior to extraordinary general meeting
GOTHENBURG, Sweden, January 20, 2023 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) (“Isofol”), yesterday called shareholders to an extraordinary
Notice convening the extraordinary general meeting in Isofol Medical AB (publ) 13 February 2023
GOTHENBURG, Sweden, January 19, 2022 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), hereby invites the shareholders of Isofol Medical
Isofol Medical CFO and Deputy CEO Gustaf Albèrt to step down during 2023
GOTHENBURG, Sweden, December 21, 2022 – Isofol Medical AB (publ) announced today that Chief Financial Officer (CFO) Gustaf Albèrt, who
Final data from the AGENT study confirms topline results
GOTHENBURG, Sweden, November 25, 2022 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL), announced today that analysis of the AGENT
Isofol Medical AB (publ) publishes interim report, January–September 2022
GOTHENBURG, Sweden, November 11, 2022 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announced today that the company’s interim report
Isofol appoints nomination committee ahead of the Annual General Meeting 2023
GOTHENBURG, Sweden, November 3, 2022 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), (”Isofol” or the ”Company”), announced today that
Isofol reports data from the AGENT study
GOTHENBURG, Sweden, 7 september 2022 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL) today reported data from the AGENT study
Bulletin from Annual General Meeting in Isofol Medical AB (publ) held on May 19, 2022
Today on May 19, 2022 in Gothenburg – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), held its annual general meeting
Isofol Medical AB (publ) publishes interim report, January–March 2022
GOTHENBURG, Sweden, May 12, 2022 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announced today that the company’s interim report